News

Jan. 20, 2020: Protease inhibitors and heart attack risk; HIV status and pericardial adipose tissue volume; cardiovascular risk profiles on TDF vs. TAF; hemostatic profiles in older people living with HIV.

We walk you through the most recent updates to official guidelines issued by the U.S. Department of Health and Human Services on the treatment and care of people living with HIV.

Feb. 13, 2020: PrEP's psychosocial benefits; supplementing ADAP with Obamacare plans; lack of HIV and HCV testing for people who inject drugs; frailty is more common, but not more deadly, in HIV settings.

While the vaginal ring is still currently under FDA review, the new study will show whether it is safe and acceptable for people who are pregnant.

Feb. 6, 2020: HIV medication costs outpace inflation; HIV's role in attenuating childhood vaccinations; the challenges of researching effects of medications during pregnancy; the need for localized HIV interventions in the U.S.

Jan. 30, 2020: Polypharmacy vs. drug interaction risk among people living with HIV as they age; cost-effectiveness of ibalizumab; PrEP persistence on Medicaid vs. private health coverage.

Jan. 23, 2020: Neurocognitive benefits of cannabis use; how unquantifiable HIV in CSF correlates to executive function; updated findings on efavirenz and microcephaly; cost-efficacy of a specialized HIV care coordination team.

Jan. 16, 2020: Texting (and stigma support) vs. email for care retention; beyond-childhood health risks for HIV-exposed infants; HIV, cardiovascular risk, and cognitive impairment; direct-acting antiviral efficacy and prescription delays.

While it is too soon to tell, this research involving broadly neutralizing antibodies could point to new methods for preventing vertical transmission.

Even with an undetectable viral load, study participants who had been vaccinated as children lost smallpox immunity.